Cargando…

Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial

PURPOSE: To compare the survival outcomes of postoperative adjuvant aspirin with surgery alone in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). METHODS: From June 2013 to July 2015, an open-label, randomized controlled study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chong-De, Jiang, Ya-Bo, Feng, Jin-Kai, Wang, Lei, Wei, Xu-Biao, Zhou, Bin, Lin, Xiao-Lu, Guo, Wei-Xing, Lau, Wan Yee, Cheng, Shu-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559736/
https://www.ncbi.nlm.nih.gov/pubmed/37810112
http://dx.doi.org/10.1016/j.heliyon.2023.e20015
_version_ 1785117569627193344
author Lu, Chong-De
Jiang, Ya-Bo
Feng, Jin-Kai
Wang, Lei
Wei, Xu-Biao
Zhou, Bin
Lin, Xiao-Lu
Guo, Wei-Xing
Lau, Wan Yee
Cheng, Shu-Qun
author_facet Lu, Chong-De
Jiang, Ya-Bo
Feng, Jin-Kai
Wang, Lei
Wei, Xu-Biao
Zhou, Bin
Lin, Xiao-Lu
Guo, Wei-Xing
Lau, Wan Yee
Cheng, Shu-Qun
author_sort Lu, Chong-De
collection PubMed
description PURPOSE: To compare the survival outcomes of postoperative adjuvant aspirin with surgery alone in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). METHODS: From June 2013 to July 2015, an open-label, randomized controlled study was conducted in patients with resectable HBV-related HCC and PVTT. Patients were randomly assigned to undergo surgical resection and postoperative adjuvant aspirin (n = 40) or hepatectomy alone (n = 40). The primary end point was overall survival (OS). The secondary end points were time to recurrence of primary tumor (t-TTR) and time to recurrence of PVTT (p-TTR). The expression levels of COX1 and COX2 in surgical specimens of the aspirin group were correlated with patients’ survival. RESULTS: The median OS were 16.2 and 13.4 months for the adjuvant aspirin and surgery alone groups, respectively. The median t-TTR were 5.3 and 3.2 months for the adjuvant aspirin and surgery alone groups, respectively. There was no significant difference in the OS and t-TTR between the two groups of patients (P = 0.078 and 0.336, respectively). The median p-TTR were 12.0 months and 5.4 months for the adjuvant aspirin group and the surgery alone group, respectively. Patients in the adjuvant aspirin group had markedly longer p-TTR (P = 0.001). Increased expressions of COX1 or COX2 in tumor tissues denoted better prognosis for patients receiving adjuvant aspirin. CONCLUSION: For patients with resectable HBV-related HCC and PVTT, postoperative adjuvant aspirin significantly prolonged time to recurrence of PVTT than surgery alone. Expression of COX1 or COX2 may predict survival in these patients.
format Online
Article
Text
id pubmed-10559736
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105597362023-10-08 Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial Lu, Chong-De Jiang, Ya-Bo Feng, Jin-Kai Wang, Lei Wei, Xu-Biao Zhou, Bin Lin, Xiao-Lu Guo, Wei-Xing Lau, Wan Yee Cheng, Shu-Qun Heliyon Research Article PURPOSE: To compare the survival outcomes of postoperative adjuvant aspirin with surgery alone in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). METHODS: From June 2013 to July 2015, an open-label, randomized controlled study was conducted in patients with resectable HBV-related HCC and PVTT. Patients were randomly assigned to undergo surgical resection and postoperative adjuvant aspirin (n = 40) or hepatectomy alone (n = 40). The primary end point was overall survival (OS). The secondary end points were time to recurrence of primary tumor (t-TTR) and time to recurrence of PVTT (p-TTR). The expression levels of COX1 and COX2 in surgical specimens of the aspirin group were correlated with patients’ survival. RESULTS: The median OS were 16.2 and 13.4 months for the adjuvant aspirin and surgery alone groups, respectively. The median t-TTR were 5.3 and 3.2 months for the adjuvant aspirin and surgery alone groups, respectively. There was no significant difference in the OS and t-TTR between the two groups of patients (P = 0.078 and 0.336, respectively). The median p-TTR were 12.0 months and 5.4 months for the adjuvant aspirin group and the surgery alone group, respectively. Patients in the adjuvant aspirin group had markedly longer p-TTR (P = 0.001). Increased expressions of COX1 or COX2 in tumor tissues denoted better prognosis for patients receiving adjuvant aspirin. CONCLUSION: For patients with resectable HBV-related HCC and PVTT, postoperative adjuvant aspirin significantly prolonged time to recurrence of PVTT than surgery alone. Expression of COX1 or COX2 may predict survival in these patients. Elsevier 2023-09-09 /pmc/articles/PMC10559736/ /pubmed/37810112 http://dx.doi.org/10.1016/j.heliyon.2023.e20015 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Lu, Chong-De
Jiang, Ya-Bo
Feng, Jin-Kai
Wang, Lei
Wei, Xu-Biao
Zhou, Bin
Lin, Xiao-Lu
Guo, Wei-Xing
Lau, Wan Yee
Cheng, Shu-Qun
Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial
title Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial
title_full Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial
title_fullStr Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial
title_full_unstemmed Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial
title_short Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial
title_sort postoperative adjuvant aspirin for patients with hepatitis b virus-related hepatocellular carcinoma and portal vein tumor thrombus: an open-label, randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559736/
https://www.ncbi.nlm.nih.gov/pubmed/37810112
http://dx.doi.org/10.1016/j.heliyon.2023.e20015
work_keys_str_mv AT luchongde postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT jiangyabo postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT fengjinkai postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT wanglei postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT weixubiao postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT zhoubin postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT linxiaolu postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT guoweixing postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT lauwanyee postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial
AT chengshuqun postoperativeadjuvantaspirinforpatientswithhepatitisbvirusrelatedhepatocellularcarcinomaandportalveintumorthrombusanopenlabelrandomizedcontrolledtrial